VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Relay Therapeutics' Zovegalisib Shows Early Promise in Rare Vascular Diseases with 60% Response Rate in Mid-Stage Trial
Relay Therapeutics' Zovegalisib Shows Early Promise in Rare Vascular Diseases with 60% Response Rate in Mid-Stage Trial
May 20, 2026 11:36 CST Updated 23:58
Share:
